Neomics develops adoptive cell therapies for cancer treatment. The leading asset, NPB5005-V283, is being developed as a best-in-class autologous BCMA-targeting CAR-T. The product contains a novel CAR transgene comprised of a potent 3.5-gen costimulatory domain and a largely truncated CD3 effector domain for effective anti-tumor activity yet attenuated CAR-T activation. In phase I investigator-initiated trial, NPB5005-V283 has shown superior clinical efficacy with significant improvement in CRS/ICANS for relapsed/refractory multiple myeloma (RRMM).